CSIRO has opened a new $23.1 million national laboratory in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and Therapeutics Lab will turn vaccine and drug candidates into products that can be manufactured in quantity for clinical trials. According to a statement from CSIRO,…
Clinical trials begin for Australian developed Covid-19 vaccines Clinical human trials have begun on subjects in Melbourne to test the effectiveness and safety of two Melbourne-developed Covid-19 vaccines. The traditional protein-based vaccine was developed by the Doherty Institute, while a mRNA vaccine was developed by Monash Institute of Pharmaceutical Sciences. Melbourne’s IDT Australia manufactured the…
IDT misses out on MMI grant for mRNA vaccines Drug manufacturer IDT Australia has missed out on a Modern Manufacturing Initiative collaboration stream grant from the federal government to further development of mRNA vaccine manufacturing capabilities. The company, which is manufacturing the vaccine components for clinical trials of a mRNA vaccine developed by Monash University,…
IDT Australia’s strong year as it develops mRNA technologies Independent pharmaceutical manufacturer IDT Australia has reported revenues up 74 per cent in the first half FY 22 to $8.56 million as its developed its capabilities in sterile manufacturing. Profit after tax was $1.21 million, up slightly from $1.12 million in the previous corresponding period. During…
By Peter Roberts Prime Minister Scott Morrison announced today that state and federal governments and vaccine producer Moderna had signed an ‘in principle’ deal for the construction of a Melbourne plant capable of utilising the newly successful vaccine production technologies that produced the Pfizer and Moderna vaccines. The plant would be capable of producing up…
By Peter Roberts It turns out those hippies who dropped out to Nimbin in the 1960s and 70s really were on to something. Their pioneering work as guinea pigs living on wisps of pot and mung beans is rapidly turning into a major industry in growing, processing and manufacture of medicinal cannabis products. Although Australia…
Building resurgence supports Adbri Building products and industrial chemicals group Adbri has reported stronger revenues and profits on the back of buoyant demand from industry and a resurgent building sector. The company saw revenue in the first half rise 7.4 per cent to $752.3 million and net profit after tax up 94.5 per cent to…
Cleanaway’s strong result in year of change Waste management group Cleanaway reported an operating profit up 3.8 per cent to $535.1 million in the year to June 30 on revenues up 4.7 per cent to $2.2 billion. Net profit after tax was $153.2 million in a year of progress for the group. Cleanaway emerged from…
By Peter Roberts Australian biotechnology and vaccine giant CSL is betting $800 million in the race to secure federal and state funding to establish mRNA vaccine in Australia. The company, which is the fourth most valuable company at $93 billion on the ASX, has outbid a group of smaller firms which are also seeking a…
By Peter Roberts Adelaide pharmaceutical group BioCina has joined the race to manufacture mRNA vaccines in Australia such as those made by Pfizer and Moderna which have proved effective in preventing infection from Covid-19. The Adelaide company, backed by the University of Adelaide, is one of a number of groups who have responded to a…